Avacopan for the Treatment of ANCA-Associated Vasculitis ASGQPL David R W Jayne 1 , Peter A Merkel 1 , Thomas J Schall 1 , Pirow Bekker 1 New England Journal of Medicine 384 (7), 599-609., 0 | 658* | |
Avacopan for the Treatment of ANCA-Associated Vasculitis ASGQPL David R W Jayne 1 , Peter A Merkel 1 , Thomas J Schall 1 , Pirow Bekker 1 New England Journal of Medicine 384 (7), 599-609., 0 | 658* | |
Eculizumab in secondary atypical haemolytic uraemic syndrome T Cavero, C Rabasco, A López, E Román, A Ávila, Á Sevillano, A Huerta, ... Nephrology Dialysis Transplantation 32 (3), 466-474, 2017 | 154 | 2017 |
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary … G Fernández-Juárez, J Rojas-Rivera, AE van De Logt, J Justino, ... Kidney international 99 (4), 986-998, 2021 | 151 | 2021 |
ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis LF Quintana, NS Peréz, E De Sousa, LM Rodas, MH Griffiths, M Solé, ... Nephrology Dialysis Transplantation 29 (9), 1764-1769, 2014 | 143 | 2014 |
Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review A Kronbichler, B Brezina, LF Quintana, DRW Jayne Autoimmunity reviews 15 (1), 38-49, 2016 | 130 | 2016 |
Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction LF Quintana, JM Campistol, MP Alcolea, E Banon-Maneus, ... Molecular & Cellular Proteomics 8 (7), 1658-1673, 2009 | 118 | 2009 |
Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis G Fernandez-Juarez, JV Perez, F Caravaca-Fontán, L Quintana, ... Clinical Journal of the American Society of Nephrology 13 (12), 1851-1858, 2018 | 112 | 2018 |
Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy A Tortajada, E Gutiérrez, EG de Jorge, J Anter, A Segarra, M Espinosa, ... Kidney international 92 (4), 953-963, 2017 | 110 | 2017 |
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 93 | 2023 |
Urine proteomics to detect biomarkers for chronic allograft dysfunction A Sole, SG Kalko, E Ban, M Sole, F Diekmann, A Gutierrez-Dalmau, ... Journal of the American Society of Nephrology 20 (2), 428-435, 2009 | 91 | 2009 |
Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy LF Quintana, M Blasco, M Seras, NS Pérez, M López-Hoyos, P Villarroel, ... Transplantation 99 (8), 1709-1714, 2015 | 89 | 2015 |
Complement activation and thrombotic microangiopathies M Palomo, M Blasco, P Molina, M Lozano, M Praga, S Torramade-Moix, ... Clinical Journal of the American Society of Nephrology 14 (12), 1719-1732, 2019 | 78 | 2019 |
Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome T Cavero, E Arjona, K Soto, F Caravaca-Fontan, C Rabasco, L Bravo, ... Kidney international 96 (4), 995-1004, 2019 | 71 | 2019 |
Refractory lupus nephritis: When, why and how to treat A Kronbichler, B Brezina, P Gauckler, LF Quintana, DRW Jayne Autoimmunity Reviews 18 (5), 510-518, 2019 | 71 | 2019 |
Pre‐transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post‐kidney transplantation G Gupta, H Fattah, R Ayalon, J Kidd, T Gehr, LF Quintana, P Kimball, ... Clinical transplantation 30 (4), 461-469, 2016 | 69 | 2016 |
Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients J Rovira, E Marcelo Arellano, JT Burke, Y Brault, D Moya‐Rull, ... Transplant International 21 (10), 992-998, 2008 | 67 | 2008 |
Clinical associations of renal involvement in ANCA-associated vasculitis A Kronbichler, JI Shin, KH Lee, D Nakagomi, LF Quintana, M Busch, ... Autoimmunity reviews 19 (4), 102495, 2020 | 66 | 2020 |
Rituximab in membranous nephropathy P Gauckler, JI Shin, F Alberici, V Audard, A Bruchfeld, M Busch, ... Kidney international reports 6 (4), 881-893, 2021 | 60 | 2021 |
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis-What is known and what is still unknown? P Gauckler, JI Shin, F Alberici, V Audard, A Bruchfeld, M Busch, ... Autoimmunity reviews 19 (11), 102671, 2020 | 55 | 2020 |